Emerging molecular mechanisms and genetic targets for developing novel therapeutic strategies for treating bladder diseases

Zoqlam, Randa, Lazauskaite, Sandra, Glickman, Scott, Zaitseva, Lyubov, Ilie, Petre-Cristian and Qi, Sheng ORCID: https://orcid.org/0000-0003-1872-9572 (2022) Emerging molecular mechanisms and genetic targets for developing novel therapeutic strategies for treating bladder diseases. European Journal of Pharmaceutical Sciences, 173. ISSN 0928-0987

[thumbnail of Revised_Manuscript]
Preview
PDF (Revised_Manuscript) - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB) | Preview

Abstract

Bladder diseases affect millions of patients worldwide and compromise their quality of life with a substantial economic impact. The not fully understood aetiologies of bladder diseases limit the current diagnosis and therapeutic options to primarily symptomatic treatment. In addition, bladder targeted drug delivery is challenging due to its unique anatomical features and its natural physiological function of urine storage and frequent voiding. Therefore, current treatment options often fail to provide a highly effective, precisely targeted and long-lasting treatment. With the growing maturity of gene therapy, comprehensive studies are needed to provide a better understanding of the molecular mechanisms underpinning bladder diseases and help to identify novel gene therapeutic targets and biomarkers for treating bladder diseases. In this review, molecular mechanisms involved in pathology of bladder cancer, interstitial cystitis and overactive bladder syndrome are reviewed, with focus on establishing potential novel treatment options. Proposed novel therapies, including gene therapy combined with nanotechnology, localised drug delivery by nanoparticles, and probiotics, are discussed in regard to their safety profiles, efficacy, treatment lenght, precise targeting, and in comparison to conventional treatment methods.

Item Type: Article
Additional Information: Funding Information: This study was supported by a UKRI Medical Research Council Doctoral Antimicrobial Research Training (DART) PhD CASE Studentship Award [grant number MR/R015937/1] and the University of East Anglia, in collaboration with UroPharma Ltd.
Uncontrolled Keywords: bladder cancer,gene therapy,interstitial cystitis, nanoparticles,overactive bladder,probiotics,pharmaceutical science ,/dk/atira/pure/subjectarea/asjc/3000/3003
Faculty \ School: Faculty of Science > School of Pharmacy
Related URLs:
Depositing User: LivePure Connector
Date Deposited: 14 Mar 2022 11:30
Last Modified: 23 Oct 2022 03:39
URI: https://ueaeprints.uea.ac.uk/id/eprint/84028
DOI: 10.1016/j.ejps.2022.106167

Actions (login required)

View Item View Item